MIR503HG: A potential diagnostic and therapeutic target in human diseases - 26/02/23
, Bo Li , Shitai Zhang ⁎ Abstract |
LncRNAs are involved in many physiological and pathological processes, including chromatin remodeling, transcription, posttranscriptional gene expression, mRNA stability, translation, and posttranslational modification, and their functions depend on subcellular localization. MIR503HG is a lncRNA as well as a host gene for the miRNAs miR-503 and miR-424. MIR503HG functions independently or synergistically with miR-503. MIR503HG affects cell proliferation, invasion, metastasis, apoptosis, angiogenesis, and other biological behaviors. The mechanism of MIR503HG in disease includes interaction with protein, sponging miRNA to regulate downstream target gene, and participation in NF-κB, TGF-β, ERK/MAPK, and PI3K/AKT signaling pathways. In this review, we summarize the molecular mechanisms of MIR503HG in disease and its potential applications in diagnosis, prognosis, and treatment. We also raise some unanswered questions in this area, providing insights for future research.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Molecular mechanism and clinical application of MIR503HG in diseases.
Molecular mechanism and clinical application of MIR503HG in diseases.ga1Le texte complet de cet article est disponible en PDF.
Highlights |
• | MIR503HG is the host gene of miR-503 and miR-424, and MIR503HG functions independently or synergistically with miRNA. |
• | Mechanisms of MIR503HG include interaction with protein, function as ceRNA, and interaction through signaling pathways. |
• | MIR503HG can be used as a biomarker of disease diagnosis and prognosis as well as a treatment target. |
Abbreviations : RBPs, EndMT, EMT, HUVEC and HPAEC, PAH, RIP, HCC, OS, TTR, OC, ChIP, ceRNA, TNBC, ER, UPR, ATF6, GC, NSCLC, DN, HG, NF-κB, PE, MMPs, NETs, TGF-β, hHSFs, CRC, ALCL, UTR, TNM, CSCC, ALK-Negative ALCL, HS, HSVEC, HCAEC, EndMT, siRNAs, ASOs, LNA
Keywords : MIR503HG, Molecular Mechanisms, Biomarker, Treatment Target
Plan
Vol 160
Article 114314- avril 2023 Retour au numéro
Article précédent
- Unraveling the therapeutic potential of natural products in the prevention and treatment of leukemia
- Harsh Goel, Rahul Kumar, Pranay Tanwar, Tarun Kumar Upadhyay, Fahad Khan, Pratibha Pandey, Sojin Kang, Myunghan Moon, Jinwon Choi, Min Choi, Moon Nyeo Park, Bonglee Kim, Mohd Saeed
- Non-coding RNAs in metabolic reprogramming of bone and soft tissue sarcoma: Fundamental mechanism and clinical implication
- Huan-Huan Chen, Peng-Hui Hao, Fang-Yuan Zhang, Tie-Ning Zhang
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?